Drug Approval | March 13, 2026
Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA
Marks significant milestone for breakthrough biologic to treat rare blood cancers
Marks significant milestone for breakthrough biologic to treat rare blood cancers
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Germany will be the first launch market
The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
Doctors recommended a robotic Strassmann Metroplasty, a reconstructive surgery that joins the two halves of the uterus into a single cavity capable of supporting pregnancy
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
Subscribe To Our Newsletter & Stay Updated
